Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Non ancora tradotto Non ancora tradotto
Categoria Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
Loading references information
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
Epistemonikos ID: 7713845763807b71e5722a54fb3b1e179b1155e4
First added on: Jul 30, 2018